ACTRN12609000655246
Not yet recruiting
Phase 4
se of aldosterone blockade to improve cardiac function in obesity
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Diastolic Dysfunction
- Sponsor
- The University of Queensland
- Enrollment
- 120
- Status
- Not yet recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Obesity: Body mass index (BMI) \> 30
Exclusion Criteria
- •Diabetes, cardiovascular disease or other chronic disease
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 3
Evaluation of spironolactone on heart related mortality and morbidity among patients undergoing chronic kidney dialysisHealth Condition 1: N186- End stage renal diseaseCTRI/2019/06/019703Population Health Research Institute
Active, not recruiting
Phase 1
Effects of Spironolactone in Heart Failure with Preserved Ejection Fraction: Measured by CMR, Echo, Excercise Capacity and Quality of Life QuestionaireEUCTR2013-000867-10-GBniversity of Leeds51
Completed
Phase 3
Therapeutic Potential for Aldosterone Inhibition in Duchenne Muscular DystrophyDuchenne Muscular DystrophyNCT02354352Ohio State University52
Completed
Not Applicable
Does aldosterone blockade improve endothelial dysfunction in patients with coronary artery disease but without heart failure?Coronary artery diseaseCirculatory SystemISRCTN70010120niversity of Dundee (UK)88
Completed
Phase 3
Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic FunctionCardiovascular DiseasesHeart DiseasesHeart Failure, CongestiveNCT00094302Carelon Research3,445